Targeting antibiotic resistance mechanisms in Mycobacterium tuberculosis: Recharging the old magic bullets

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 9, 2012, Pages 963-965

  Nguyen, Liem ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotic; drug development; drug resistance; infectious diseases; magic bullets; mycobacterium; targeting resistance; tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CLAVULANIC ACID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MEROPENEM; NALIDIXIC ACID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN B; RIFAMYCIN S; RIFAPENTINE; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84868145984     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.85     Document Type: Review

References (19)

1. Zhang Y. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 45, 529-564 (2005).
2. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 46(2), 267-274 (2002).
3. Nguyen L, Pieters J. Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development. Annu. Rev. Pharmacol. Toxicol. 49, 427-453 (2009).
4. Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 67(4), 286-288 (2012).
5. Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat. Med. 13(3), 295-298 (2007).
6. Bolten BM, DeGregorio T. From the analyst's couch. Trends in development cycles. Nat. Rev. Drug Discov. 1(5), 335-336 (2002).
7. Davies J. Afterword. Learning and teaching: a perspective reflection. In: Frontiers in Antimicrobial Resistance: A Tribute to Stuart B. Levy. White DG, Alekshun MN, Mcdermott PF (Eds). ASM Press, Washington, DC, USA 551-554 (2005).
8. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 469(7331), 483-490 (2011).
9. D'Costa VM, King CE, Kalan L et al. Antibiotic resistance is ancient. Nature 477(7365), 457-461 (2011).
10. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 311(5759), 374-377 (2006).
11. Chikamatsu K, Mizuno K, Yamada H, Mitarai S. Crossresistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains. Kekkaku 84(9), 631-633 (2009).
12. Senol G, Erbaycu A, Ozsöz A. Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J. Chemother. 17(4), 380-384 (2005).
13. Gordin FM. Rifapentine for the treatment of tuberculosis: is it all it can be? Am. J. Respir. Crit. Care Med. 169(11), 1176-1177 (2004).
14. Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol. Pharm. 66(6), 587-604 (2009).
15. Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 55(12), 5421-5429 (2011).
16. Wright GD. Resisting resistance: new chemical strategies for battling superbugs. Chem. Biol. 7(6), R127-R132 (2000).
17. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenemclavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215-1218 (2009).
18. Willand N, Dirié B, Carette X et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537-544 (2009).
19. Weber W, Schoenmakers R, Keller B et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105(29), 9994-9998 (2008).